Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma
Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma
About this item
Full title
Author / Creator
Publisher
San Francisco: Public Library of Science
Journal title
Language
English
Formats
Publication information
Publisher
San Francisco: Public Library of Science
Subjects
More information
Scope and Contents
Contents
Lenvatinib is an oral anticancer medication used to treat radioiodine-refractory thyroid cancer and unresectable hepatocellular carcinoma. The purpose of this study is to evaluate lenvatinib adherence by patients and to identify factors associated with decreased lenvatinib adherence. Among 153 patients who started treatment with lenvatinib for unre...
Alternative Titles
Full title
Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_plos_journals_3069280805
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_3069280805
Other Identifiers
ISSN
1932-6203
E-ISSN
1932-6203
DOI
10.1371/journal.pone.0294320
